Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-blind, Placebo Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Expanded Autologous Adipose-derived Stem Cells (ASCs) (CX-401), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease

NCT01378390 is registered in ClinicalTrials.gov with Tigenix S.A.U. as lead sponsor.

NCT NCT01378390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01378390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-blind, Placebo Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Expanded Autologous Adipose-derived Stem Cells (ASCs) (CX-401), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease
Lead sponsor
Tigenix S.A.U.
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2008
Completion date
February 28, 2010
Enrollment
56 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

complex perianal fistula, crohn disease